核呼吸因子1促进蛋白酶体抑制治疗下多发性骨髓瘤细胞存活
研究对55例多发性骨髓瘤患者的CD138+细胞行ATAC-seq与计算足迹分析,发现核呼吸因子1(NRF1)是维持蛋白酶体稳态的关键调控因子;靶向NRF1增强子RNA可降低NRF1水平并增加肿瘤细胞对硼替佐米的敏感性,在异种移植模型中靶向该增强子的反义寡核苷酸单用或联合硼替佐米均显著降低肿瘤负荷并改善生存。
要点
- NRF1通过协调泛素化通路维持蛋白酶体稳态,对多发性骨髓瘤细胞存活至关重要。
- 新发现的增强子元件与NRF1启动子物理互作以维持其表达。
- 靶向NRF1增强子的反义寡核苷酸单用或联合硼替佐米在异种移植模型中显著降低肿瘤负荷并改善生存。
核心结论
- 研究揭示了既往未知的NRF1依赖机制调控多发性骨髓瘤细胞存活,并提示通过操控其调控网络可能成为有前景的治疗途径。
研究设计与样本
- 研究采用转座酶可及染色质高通量测序分析(ATAC-seq)结合计算足迹分析,检测55例多发性骨髓瘤患者CD138+细胞。
- 研究使用异种移植模型评估靶向NRF1增强子的反义寡核苷酸单用或联合硼替佐米的效应。
主要发现
- 研究描绘了疾病进展过程中染色质可及性的动态变化,并确定NRF1为多发性骨髓瘤关键存活通路的主调控因子。
- NRF1通过协调泛素化通路维持蛋白酶体稳态,这对多发性骨髓瘤细胞存活必不可少。
- 研究发现一个新的增强子元件与NRF1启动子物理互作,维持NRF1表达。
- 靶向该增强子RNA可降低NRF1水平并增加肿瘤细胞对硼替佐米(BTZ)的敏感性。
- 在异种移植模型中,靶向NRF1增强子的反义寡核苷酸单用或联合BTZ均显著降低肿瘤负荷并改善生存。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma (MM) continues to be an incurable malignancy, even with recent therapeutic advancements. Although epigenetic dysregulation at cis-regulatory elements is known to drive disease progression, the complete molecular mechanisms underlying these alterations are poorly understood. Using Assay for Transposase-Accessible Chromatin with high-throughput sequencing analysis combined with the computational footprinting of CD138+ cells from 55 patients with MM, we depicted the dynamic changes in chromatin accessibility during disease progression and identified nuclear respiratory factor 1 (NRF1) as a master regulator of vital MM survival pathways. We demonstrated that NRF1 maintains proteasome homeostasis by orchestrating the ubiquitination pathway, which is essential for MM cell survival. We discovered a novel enhancer element that physically interacts with the NRF1 promoter, sustaining its expression. Targeting this enhancer RNA reduced NRF1 levels and increased tumor cell sensitivity to bortezomib (BTZ), suggesting therapeutic potential. In xenograft models, we showed that antisense oligonucleotides targeting the NRF1 enhancer, either alone or combined with BTZ, significantly decreased tumor burden and improved survival. Our findings reveal a previously unknown NRF1-dependent mechanism regulating MM cell survival and present a promising therapeutic approach through the manipulation of its regulatory network.
引用
- Bruno T, Cappelletto MC, Cortile C, et al. Nuclear respiratory factor 1 promotes cell survival in multiple myeloma under proteasome inhibition therapy. Blood. 2025. PMID: 40920573. doi:10.1182/blood.2025028441
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。